Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2469-2478

  Decrausaz, Loane ^a   Revaz, Véronique ^a   Bobst, Martine ^a   Corthésy, Blaise ^a   Romero, Pedro ^b   Nardelli Haefliger, Denise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

Cervical cancer; Human papillomavirus; Mucosal immunity; Therapeutic vaccination

Indexed keywords

GAMMA INTERFERON; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; ANIMAL; C57BL MOUSE; FEMALE GENITAL SYSTEM; IMMUNOLOGY; MUCOSA; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ALPHAPAPILLOMAVIRUS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENITALIA, FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MUCOUS MEMBRANE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 77951218114     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24949     Document Type: Article

References (48)

1. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24S3:S3/11-S3/25.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265 (Pubitemid 34293391)
3. Lowy D, Schiller J. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-1173
4. Kanodia S, Da Silva DM, Kast M. Recent advances in strategies for immunotherapy on human papillomavirus-induced lesions. Int J Cancer 2008;122:247-259 (Pubitemid 350234709)
5. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermund SH, Heyward WL, Nelson A, Reeves WC. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int J Cancer 1992;50:45-48
6. Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-692 (Pubitemid 17181893)
7. Sun XV, Kuhn L, Ellerberock RV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-1349 (Pubitemid 27467768)
8. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jong BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249
9. Lin KY, Guarnieri FG, Staveleyocarroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26
10. Woo Y, Sterling JC, Damay I, Coleman N, Crawford R, van der Burg SH, Stanley MA. Characterising the local immune responses in cervical intraepithelial neoplasia: a crosssectional and longitudinal analysis. BJOG 2008;115:1616-1621
11. Roden R, Ling M, Wu T-C. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004;35:971-982 (Pubitemid 39037180)
12. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005;32:S72-S81.
13. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV16) virus-like particles or with the HPV16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999;73:9063-9071 (Pubitemid 29487059)
14. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166:3451-3457 (Pubitemid 33117348)
15. Gherardi MM, Pérez-Jiménez E, Nàjera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004;172:6209-6220 (Pubitemid 38621227)
16. Milligan GN, Dudley-McClain KL, Chu CF, Young G. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 2004;318:507-515
17. Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell W, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007;25:3302-3310 (Pubitemid 46527998)
18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;5:342-350
19. Gluck U, Gebbers JO, Gluck R. Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 1999;73:7780-7786 (Pubitemid 29383262)
20. Revaz V, Debonneville A, Bobst M, Nardelli-Haefliger D. Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse-transcription-PCR. Clin Vaccine Immunol 2008;5:757-764 (Pubitemid 351967021)
21. Slade SJ, Langhorn J. Production of interferon-gamma during infection of mice with Plasmodium chabaudi chabaudi. Immunobiology 1989;179:353-365 (Pubitemid 19268311)
22. Coles RM, Mueller SN, Heath WF, Carbone FR, Brooks AG. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus. J Immunol 2002;168:834-838
23. Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of Cholera Toxin. J Immunol 2006;176:2749-2757 (Pubitemid 43306933)
24. Stewart TJ, Smyth MJ, Fernando GJP, Frazer IH, Leggatt GR. Inhibition of early tumor growth required Ja18-positive (natural killer T) cells. Cancer Res 2003;63:3058-3060
25. Belyakov IM, Ahlers JD. Comment on "trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination." J Immunol 2009;182:1779-1780
26. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996;184:1879-1890
27. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA 1998;95:1709-1714 (Pubitemid 28103458)
28. Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 2002;186:1098-1105 (Pubitemid 35177112)
29. Suvas PK, Dech HM, Sambira F, Zeng J, Onami TM. Systemic and mucosal infection program protective memory CD8 T cells in the vaginal mucosa. J Immunol 2007;179:8122-8127
30. Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJE, Goudsmit J, Barouch DH. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol 2008;181:4188-4198
31. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/ human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007;178:7211-7221 (Pubitemid 46847447)
32. Liu H, Wu HB, Rowse GJ, Emtage PC. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. Clin Vaccine Immunol 2007;8:1013-1023
33. Wakabayashi MT, Da Silva DM, TPotkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 2002;45:300-307
34. Ohlschlager P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidated (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006;5:2880-2893
35. Hsieh CH, Kim TW, Hung C, Juang J, Moniz M, Boyd A, He L, Chen J, Chen CH, Wu TC. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004;22:3993-4001. (Pubitemid 39208763)
36. Welters MJP, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn ARPM, van der Marel GA, Overskleeft HS, Lipford GB, Offringa R, Melief CJ, van Boom JH, et al. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 2004;23:305-311 (Pubitemid 39463046)
37. Préville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005;65:641-649
38. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 2002;5:62-69 (Pubitemid 34118159)
39. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004;199:201-216 (Pubitemid 38736773)
40. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005;23:1804-1813
41. McCluskie MJ, Weeratna RD, Clements JD, Davis HL. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 2001;19:3759-3768
42. Chen CH, Wang TL, Hung CF, Yang YQ, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-1042
43. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216-225 (Pubitemid 30662070)
44. Greenstone HL, Nieland JD, Devisser KE, Debruijn M, Kirnbauer R, Roden R, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the e7 oncoprotein in an hpv16 tumor model. Proc Natl Acad Sci USA 1998;95:1800-1805 (Pubitemid 28103474)
45. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-888 (Pubitemid 29249972)
46. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-6479 (Pubitemid 33081581)
47. Berraondo P, Nouzé C, Préville X, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive and regulatory components of the immune system. Cancer Res 2007;18:8847-8855 (Pubitemid 47437461)
48. Piersma SJ, Jordanova ES, van Poelgeest MIE, Kwappenberg KMC, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ Tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-361 (Pubitemid 46142795)